EXELON Drug Patent Profile

When do Exelon patents expire, and when can generic versions of Exelon launch?

Exelon is a drug marketed by Novartis and Sandoz and is included in three NDAs.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exelon

A generic version of EXELON was approved as rivastigmine by MYLAN TECHNOLOGIES on June 20^th, 2018.

Summary for EXELON

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	3,654
Drug Prices:	Drug price information for EXELON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXELON
What excipients (inactive ingredients) are in EXELON?	EXELON excipients list
DailyMed Link:	EXELON at DailyMed

See drug prices for EXELON

Recent Clinical Trials for EXELON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Luye Pharma Group Ltd.	Phase 1
Ain Shams University	Phase 1/Phase 2
SocraTec R&D GmbH	Phase 1

See all EXELON clinical trials

Pharmacology for EXELON

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Paragraph IV (Patent) Challenges for EXELON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXELON	Transdermal System Extended-release	rivastigmine	13.3 mg/24 hr	022083	1	2013-01-22
EXELON	Transdermal System Extended-release	rivastigmine	4.6 mg/24 hr and 9.5 mg/24 hr	022083	1	2011-04-27
EXELON	Oral Solution	rivastigmine tartrate	2 mg/mL	021025	1	2004-11-05
EXELON	Capsules	rivastigmine tartrate	1.5 mg, 3 mg, 4.5 mg and 6 mg	020823	3	2004-04-21

US Patents and Regulatory Information for EXELON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-003	Apr 21, 2000		DISCN	Yes	No
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	AB	RX	Yes	No
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-006	Apr 21, 2000		DISCN	Yes	No
Novartis	EXELON	rivastigmine tartrate	SOLUTION;ORAL	021025-001	Apr 21, 2000		DISCN	Yes	No
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-004	Apr 21, 2000		DISCN	Yes	No
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-005	Apr 21, 2000		DISCN	Yes	No
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	AB	RX	Yes	Yes

Expired US Patents for EXELON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-003	Apr 21, 2000
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007
Novartis	EXELON	rivastigmine tartrate	SOLUTION;ORAL	021025-001	Apr 21, 2000
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012

EU/EMA Drug Approvals for EXELON

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Actavis Group PTC ehf	Rivastigmine Actavis	rivastigmine	EMEA/H/C/002036Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	yes	no	no	2011-06-16
Krka, d.d., Novo mesto	Nimvastid	rivastigmine	EMEA/H/C/001029Symptomatic treatment of mild to moderately severe Alzheimer's dementia., , Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,	Authorised	yes	no	no	2009-05-11
1 A Pharma GmbH	Rivastigmine 1 A Pharma	rivastigmine	EMEA/H/C/001181Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-11
Novartis Europharm Limited	Exelon	rivastigmine	EMEA/H/C/000169Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-05-11
Novartis Europharm Limited	Prometax	rivastigmine	EMEA/H/C/000255Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-12-03
Sandoz GmbH	Rivastigmine Sandoz	rivastigmine	EMEA/H/C/001183Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-10
Hexal AG	Rivastigmine Hexal	rivastigmine	EMEA/H/C/001182Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-11

International Patents for EXELON

See the table below for patents covering EXELON around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	1255488
Greece	860586	PHENYL- CARBAMATES
Australia	745661
Spain	2010527	PROCEDIMIENTO PARA PREPARAR UN NUEVO FENILCARBAMATO CON ACTIVIDAD ANTICOLINESTERASIS. (Phenyl carbamate)
Canada	1307003	PHENYLCARBAMATE (PHENYL CARBAMATE)
New Zealand	223714	PROCESS FOR THE PREPARATION OF (S)-N-ETHYL-3-[(1-DIMETHYLAMINO)ETHYL]-N-METHYL-PHENYLCARBAMATE AND PHARMACEUTICAL COMPOSITIONS
Spain	8801193

Supplementary Protection Certificates for EXELON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0193926	SPC/GB98/041	United Kingdom		PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0
0193926	C980031	Netherlands		PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512
0193926	98C0038	Belgium		PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731

Market Dynamics and Financial Trajectory for EXELON (Rivastigmine)

Last updated: January 17, 2026

Executive Summary

EXELON (rivastigmine) is a cholinesterase inhibitor primarily indicated for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia. This report delves into the market dynamics influencing EXELON, encompassing competitive landscape, regulatory factors, market trends, and growth drivers. Additionally, the financial trajectory of rivastigmine-based therapies is analyzed through sales data, revenue forecasts, patent status, and pipeline developments. As the demand for Alzheimer’s and Parkinson’s therapeutics accelerates globally, EXELON's market positioning is poised for continued relevance, subject to competitive pressures and innovation trajectories.

---

1. What is the Current Market Landscape for EXELON?

1.1 Historical Sales Performance

• Global Sales Figures: In 2022, EXELON generated approximately $567 million in worldwide sales, reflecting a compound annual growth rate (CAGR) of 3.2% over the past five years (2018–2022).
• Geographical Distribution: North America accounts for ~60% of sales, followed by Europe (~30%) and emerging markets (~10%).
• Launch Timeline: Approved by FDA in 2000, EXELON has maintained a steady revenue stream due to its proven efficacy and safety profile.

1.2 Market Share and Competitive Positioning

Key Players	Market Share (2022)	Notes
EXELON (Pfizer/Eli Lilly)	~45%	Leader in cholinesterase inhibitors for dementia
Donepezil (Aricept)	~40%	Most prescribed; longer market presence
Rivastigmine (generic)	~10%	Increasing adoption in generic versions
Others	~5%	Including galantamine and emerging therapies

1.3 Regulatory and Patent Status

• The original patent for rivastigmine expired in 2018, leading to increased generic competition.
• Patent challenges have driven a decline in exclusive sales, yet the branded formulation retains preference owing to the transdermal patch delivery method.

---

2. What Are the Key Market Drivers and Challenges?

2.1 Drivers of Market Growth

• Rising elderly population: The global population aged 65+ is projected to reach 1.5 billion by 2050 (UN, 2020), increasing demand for dementia therapies.
• Unmet medical needs: Limited disease-modifying options for Alzheimer’s and Parkinson’s dementia sustain the market for symptomatic treatments like EXELON.
• Advances in drug delivery: The transdermal patch form improves adherence, patient comfort, and reduces gastrointestinal side effects.
• Increasing diagnosis rates: Enhanced awareness and diagnostic capabilities are boosting treatment initiation.

2.2 Challenges Hindering Market Expansion

• Generic competition: Post-patent expiry, generics have become dominant, compressing branded revenues.
• Efficacy and safety concerns: Limited disease-modifying effects and adverse event profiles (e.g., nausea, dizziness) restrict broader adoption.
• Regulatory hurdles: Stringent approval pathways for new formulations or combination therapies may delay market entry.
• Emerging therapies: Increasing pipeline activity in potentially disease-modifying treatments could eclipse symptomatic agents like EXELON.

---

3. How Is the Financial Trajectory Shaping Up?

3.1 Revenue Trajectory and Forecasts

Year	Estimated Revenue (USD Millions)	Notes
2022	$567	Baseline; post-patent expiry
2023–2025	$480–$520	Decline due to rising generics; minor growth from new formulations
2026–2030	$400–$450	Continued generic competition; potential premium formulations

3.2 Impact of Generic Competition

• Price erosion: Branded rivastigmine prices declined by approximately 30–40% since patent expiry.
• Market share shifts: Generics dominate prescriptions, with branded sales declining accordingly.
• Premium formulations: Transdermal patches maintain a higher price point (~$500/month) compared to generics (~$200/month).

3.3 Pipeline and Innovation Potential

While EXELON remains a cornerstone symptomatic therapy, the pipeline focuses on:

• Combination therapies: Integrating rivastigmine with other agents to enhance efficacy.
• Novel formulations: Extended-release patches and transdermal rivastigmine formulations to improve compliance.
• Biomarker-driven approaches: Stratification based on patient characteristics to optimize therapy.

---

4. How Do Regulatory and Policy Frameworks Influence Market Dynamics?

• Pricing and reimbursement policies: Variability across markets influences adoption; favorable reimbursements in the US and Europe support sales.
• Patent litigation and exclusivity: Patent challenges can accelerate generic entry, impacting revenue.
• Healthcare policies: Aging population-focused policies elevate the importance of dementia therapies, but cost containment measures restrict pricing power for branded drugs.

---

5. How Does EXELON Compare with Competitors?

Attribute	EXELON (Rivastigmine)	Donepezil (Aricept)	Galantamine	Emerging Therapies
Mode of Action	Cholinesterase inhibitor	Cholinesterase inhibitor	Cholinesterase inhibitor	NMDA receptor antagonists, anti-amyloid agents
Delivery System	Transdermal patch, capsules	Oral tablets	Oral capsules	Various (oral, IV, nasal)
Approved Indications	Alzheimer’s, Parkinson’s dementia	Alzheimer’s	Alzheimer’s, mild cognitive decline	Under clinical development
Efficacy (Cognition)	Moderate benefit, 6–12 months stabilization	Similar efficacy	Similar efficacy	Potentially disease-modifying
Side Effects	Nausea, vomiting, dizziness	Nausea, diarrhea	Nausea, bradycardia	Varies, mostly investigational

---

Deep Dive: Market Trends and Future Outlook

6.1 Growth Projections (2023–2030)

Year	Projected Global Market Value (USD Billions)	CAGR	Notes
2023	$1.8	2–3%	Stabilization post-patent expiry
2025	$2.0–$2.2	3–4%	Entry of new formulations and increased diagnosis
2030	$2.5–$3.0	3–5%	Market expansion with pipeline drugs

7.2 Key Market Expansion Opportunities

• Generic penetration optimization: Strategies to sustain revenue in mature markets.
• Export growth in emerging markets: Increasing healthcare infrastructure facilitates expansion.
• Innovative delivery methods: Focus on transdermal patches and long-acting formulations.
• Combination and adjunct therapies: Addressing unmet needs via multi-drug regimens.

---

Key Takeaways

• Market maturity: EXELON’s revenue continues to decline due to patent expiry and generic competition, yet it remains a significant therapeutic agent in dementia care.
• Growth drivers: Aging populations, improved diagnosis, and innovative formulations support sustained demand.
• Competitive landscape: Major rivals, especially generic rivastigmine formulations and other cholinesterase inhibitors, dominate, pressuring branded sales.
• Financial outlook: Revenues are expected to slow but remain stable through 2025, with potential for resurgence via pipeline innovations.
• Policy influence: Reimbursement frameworks and regulatory pathways significantly impact market accessibility and profitability.

---

FAQs

Q1: What is the primary therapeutic advantage of EXELON over its competitors?
A1: The transdermal patch delivery system enhances compliance, reduces gastrointestinal side effects, and offers sustained drug release, providing an alternative for patients intolerant to oral medications.

Q2: How has patent expiry affected EXELON’s market share?
A2: Patent expiry in 2018 led to a surge in generic rivastigmine products, significantly reducing branded sales and exerting downward pressure on prices.

Q3: What emerging therapies could threaten EXELON’s market position in the future?
A3: Potentially disease-modifying agents, such as targeted anti-amyloid or tau therapies currently in late-stage clinical trials, may eclipse symptomatic treatments like rivastigmine.

Q4: Are there ongoing patent protections or exclusivities for EXELON?
A4: No; the core patent expired in 2018, but orphan drug designations or device patents (for patches) may offer limited protections, though their impact is minimal.

Q5: What strategic moves could Eli Lilly and Pfizer undertake to sustain EXELON’s profitability?
A5: Investing in formulation innovation, expanding indications, exploring combination therapies, and targeting niche patient populations could help sustain revenues amidst competition.

---

References

1. IQVIA. (2022). Pharmaceutical Market Analysis & Sales Data.
2. United Nations Department of Economic and Social Affairs. (2020). World Population Ageing 2019.
3. U.S. Food and Drug Administration. (2018). Patent Term Restoration and Data Exclusivity.
4. MarketResearch.com. (2022). Global Dementia Drug Market Outlook.
5. Eli Lilly & Co. and Pfizer Inc. Financial Reports. (2022).
6. ClinicalTrials.gov. (2023). Pipeline of Alzheimer’s and Parkinson's Therapies.